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1. Introduction 
Medulloblastoma is one of the most common childhood tumour of the central nervous 
system. During the past years several researchers dealt with its aetiology, pathology and 
therapy: surgical-, radio- and chemotherapy. The objective of the present chapter is to 
review the chemotherapy and we shall present our results and the few clinical data about 
the targeted therapy. 
2. Incidence 
Tumours of the central nervous system (CNS) are the second most common childhood 
malignant diseases after hematological malignancies. The incidence is similar in the 
different developed countries: in Europe is 29.9/million (1978-1997), in USA 30.7/million 
(1992-2006). However, the highest incidence is registered in Hungary and the Scandinavian 
countries. In Hungary the incidence was 37.41/million between 1999 and 2008 and 
43.9/million in 2009. The cause of this high incidence in Hungary is unknown (Gupta & 
Banerjee et al, 2004; Hauser et al., 2003; Kaderali et al., 2009; McNeil et al., 2002; Peris-Bonet 
et al., 2006; Pizzo & Poplack, 2011). Astrocytomas and medulloblastoma are the most 
frequent among childhood CNS tumours. 
3. Prognostic factors 
The prognostic factors are especially important in risk group assignment of brain tumours, 
because the increased intensity of treatment in high risk cases has much more side effects, 
than the therapy of the average risk patients. 
The most frequently used prognostic factors in the past were: the size of the tumour, the 
metastases including the tumour cells in the spinal fluid 2 weeks after the surgery (Chang 
(T1-4; M0-3) (Laurent et al., 1985) and the extent of the surgical intervention (Albright et al., 
1996). Later the age and the histology of tumour were also introduced (Ellison, 2010; 
Giangaspero et al., 2006; Packer et al., 1994). According to several publications residual 
tumour mass greater than 1.5 cm2 after the surgical intervention, the presence of metastases, 
age younger than 3 years are unfavourable prognostic factors (Albright et al., 1996; Chang et 
al., 1969; Eberhart et al., 2002; Jenkin et al., 2000; Klesse & Bowers, 2010) The histology of the 
tumours (desmoplastic/nodular, classic, large cell/anaplastic) is an important, independent 
prognostic factor too, which was proved by Rutkowski et al. in a study of 260 young 
children (Rutkowski et al, 2010). 
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Several biological factors have prognostic value (ERBB2, TP53, PDGFRA, TRKC, CDK6, ǂ 
and ǃ-catenin). The prognostic role of the aberrantly expressed miRNAs is yet under 
investigation (Birks et al., 2011). However, the most reliable and independent prognostic 
factor is microarray gene expression profile (Aihara et al., 2010; Fernandez-T et al., 2004; 
Pizzo & Poplack, 2010; Rutkowski et al., 2010; Tabori et al., 2010). Four distinct groups were 
established by Northcott (Northcott et al., 2010): Wnt, Shh, C and D. Wnt and Shh was 
previously described as the wingless type and sonic hedgehoge pathway involvement in the 
tumorproliferation (Wechsler-Reya & Scott, 2001). In Group C and D a clear molecular 
pathway involvement could not be clearly identified. The new classification does not follow 
the classical pathological classification (as classic, desmoplastic, large cell/anaplastic 
subtypes) and it shows some association with age and metastatis production. The separation 
of these groups by immunohistochemical analysis only was a great step toward the 
everyday practice in using this classification as prognostic factor. Group Wnt, Shh, C, D are 
characterized by the presence of CTNNB1, GLI1, NPR3 and KCNA1 proteins. Wnt and Shh 
groups seem to need less intensive therapy with outstanding survival and less side effects. 
Most centres use the following prognostic factors: the young age (<3 years) residual tumour 
after surgery, the metastases, the histology and in some centres the MYCC/MYCN 
amplification and the expression of ERBB2 (Pizzo & Poplack, 2010; Rutkowski et al., 2010; 
Takei et al., 2009). 
4. Therapy 
The therapy of the malignant tumours is surgical, radio- and chemotherapy, similarly to 
other childhood tumours. In brain tumours the most important is the surgical therapy and is 
curative if it is radical ablation and no metastases are found. However, the surgical therapy 
is hindered by the localisation of the tumour and the difficulty in differentiating the tumour 
from the normal tissues. 
The radiotherapy of medulloblastoma is an important and effective part of therapy. 
However its use is limited by the irreversible damage caused in children, which is specially 
serious in young children and infants causing serious neurocognitive damage (Fouladi et al., 
2005; Mulhern et al., 2004). Hence it should be avoided in children less than 3 years old in 
spite of their lower survival rate (Johnston et al., 2009). It is remarkable, that the increased 
intensity of the chemotherapy enabled the decrease of the craniospinal radiation dose in the 
average risk cases without the worsening the survival to 23.4Gy along an unchanged focus-
dose (55.8Gy) which decreased significantly the late side-effects (Mulhern et al., 1998; Packer 
et al., 1999, 2006). 
4.1 Chemotherapy 
It is difficult to compare the different studies to select the optimal treatment protocol due to 
the non-uniform prognostic factors, the lack of reliable – centrally checked – patho-
histological and molecular diagnostics and the often low number of patients and duration of 
observation. Hoff (von Hoff et al., 2009) and collaborators published the results of a 10 years 
long follow up. In their patient-group 12% of relapse occurred five years or more after the 
end of therapy. 
An important obstacle of the chemotherapy is the blood-brain barrier despite the fact that 
the tumour breaks through the barrier when growing. There were several trials for 
increasing the possibility of passing the barrier but without any provable result. (Kobrinsky 
et al., 1999; Prados et al., 2003) 
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The additive curative effect of chemotherapy after surgery and radiotherapy was proved by 
a prospective, multicentric, randomised trial in 1990 (Evans et al., 1990; Tait et al., 1990). In 
the beginning vincristine and the nitrosoureas were applied, which are still used in several 
protocols for the treatment of medulloblastoma. However, the usefulness of vincristine was 
recently challenged because vincristine could not be detected in the spinal fluid in 
measurable concentration after 1,5 mg/m2 i.v. bolus injection. Later more and more 
chemotherapeutic drug combinations have been used. The key agents are the nitrosoureas 
(lomustine, carmustine), cyclophosphamide, vincristine and the later used cisplatin, 
carboplatin, and etoposide (Mueller & Chang, 2009). Some protocols apply ifosfamide 
alternating with cyclophosphamide (Park et al., 2010). The application of methotrexate is 
limited not only because of its potential side effects, but also because it can be used only 
before radiotherapy, however, some protocols described rather good results in cases when 
no irradiation was done (Bleyer, 1981; Chi et al., 2004; Fossati-Bellani et al., 1990; Rutkowski 
et al., 2005). The alkylating oral drug dibromdulcitol was an excellent substance for the 
treatment of medulloblastomas because its favourable pharmacokinetic properties in the 
spinal fluid and its tolerable toxicity (Paál et al., 1994; Schuler et al., 1988, 1992). Later in 
spite of the good clinical results the drug became unavailable. However, this may be 
partially substituted by temozolomide, but there is no study yet, which proves its efficacy in 
medulloblastoma. 
The increased arsenal of the chemotherapeutics and the higher intensity of the treatment 
resulted in improved survival. In cases with favourable prognosis the survival rate is 
already over 80%, and around 70% in cases with unfavourable prognosis (Gottardo & Gajjar, 
2008). However, the toxicity of the treatment increased, too. Therefore, besides improving 
survival rates reducing early and late toxicity are also important.  In the future a less toxic 
treatment is expected thanks to the development of the targeted molecular therapy based on 
tumour-biological knowledge. 
The most important criteria are: 
1. the optimal timing of the chemotherapy 
2. the most effective combination of cytostatics 
3. sufficient intensity and length of the chemotherapy 
4. a tolerable toxicity of the drugs used in the protocol. 
 Some trials proved that the chemotherapy given before and after the irradiation (sandwich 
therapy) is disadvantageous; the survival is shorter if the radiotherapy is longer than 50 
days (von Hoff et al., 2009; Taylor et al., 2003). Hence the radiotherapy should be given as 
early after the surgery as it is possible (Bailey et al., 1995; Kortmann et al., 2000). During the 
radiotherapy several protocols contain the administration of vincristine (von Hoff et al., 
2009; Packer et al., 1994, 1999) or in one protocol carboplatin (Jakacki et al., 2007). A 
preoperative chemotherapy is applied in several paediatric tumours, because it decreases 
the size of the tumour and facilitate the tumour removal. Hence it would be reasonable to 
introduce it in huge chemosensitive brain tumours, too (Schuler et al., 1993). The 
preoperative chemotherapy is feasible and safe in children with high risk medulloblastoma 
according to some pilot trials (Di Rocco et al., 1995; Grill et al., 2005; Schuler et al., 1993). 
However, it is not applied in the practice up to now. 
In most protocols a combination of vincristine, a nitrosourea (lomustine or camustine) and a 
platinum compound (cisplatin or carboplatin) is used. In several protocols 
cyclophosphamide is used instead of nitrosourea because of the good antitumour effect and 
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shorter bone marrow toxicity of cyclophosphamide, (von Hoff et al., 2009; Mueller & Chang, 
2009; Packer et al., 1994) and in some treatment protocols etoposide is also added  to this 
combination (Chi et al., 2004; Dhall et al., 2008; Hauser et al., 2009). 
Our protocol for average risk cases begins with three intrathecal triplet (methotrexate, ara-C, 
prednisolone) and VECp-block (vincristine, cyclophosphamide, etoposide) after the surgery. 
This is followed by radiotherapy (5th - 11th week). During the radiotherapy the patients get 
weekly vincristine. 2 weeks after the radiotherapy chemotherapy is continued by vincristine 
― etoposide ― cyclophosphamide/ carboplatin; vincristine ― cisplatin ― etoposide / BCNU 
blocks until the 73nd postoperative week. 
In high risk cases autologous stem cell transplantation is made after the 40th postoperative 
week instead of maintenance therapy. If a residual tumour is present it is removed by a 
“second look” surgery before the transplantation. 
In children less than 3 years old the therapy is similar to that in high risk cases, except that 
no radiotherapy is given and the stem cell transplantation is made as soon as no tumour is 
seen by MRI. Radiotherapy is given only, if the tumour is still present after the age of three 
years. 
The toxicity of our protocol was tolerable; and there was no therapy related mortality. After 
31 months the overall survival was 79% in the average risk patients and 63% in high risk 
patients. 
The best therapeutic results in average risk cases were achieved by the multicentre trial 
HIT’91 (von Hoff et al., 2009). The overall survival in patients without metastasis was 91% 
after 10 years. After the removal of tumour a combination of radiotherapy and vincristine 
was applied, which was followed 6 weeks later by 8 cycles with lomustine (CCNU), 
vincristine and cisplatin. Packer et al., described a 86% survival after 3 years follow up by a 
similar regime (Packer et al., 1999). A 93% survival was published by Strother et al. (2001) 
(Strother et al., 2001) with a more aggressive therapy. They administered 4 cycles of high 
dose chemotherapy after surgery and radiotherapy (cyclophosphamide, cisplatin, and 
vincristine) followed by auto-transplantation after each cycle. 
The results in high risk cases are more consistent ranging from 34 to 40% across studies 
(Mueller & Chang, 2009). However, Chi et al. achieved 60% overall survival after 3 years by 
5 cycles of vincristine, cisplatin, etoposide, cyclophosphamide and methotrexate given after 
surgery followed by myeloablative chemotherapy with autologous stem cell rescue (Chi et 
al., 2004). The results of Gajjar et al. (Gajjar et al., 2006) was similar: 83% event free survival 
in average risk patients and 70% in high risk cases after 5 years. 
Good survival was achieved by the COG99701 study (Jakacki et al., 2007). They 
administered vincristine and carboplatin during the radiotherapy in patients with metastatic 
medulloblastoma. 6 weeks later the patients received 6 courses of monthly 
cyclophosphamide and vincristine. The overall survival after 4 years was 81%. 
The increased intensity of therapy resulting a longer survival has more late side effect. 
Hence the stratification of the tumours according to prognostic factors into average or high 
risk group is important. 
In cases of medulloblastomas of children less than 3 years old radiotherapy should avoid. 
The most favourable approach after surgery is the myeloablative consolidation 
chemotherapy after conventional induction therapy which may result 60% overall survival 
after 3 years (Chi et al., 2004). The result of the intensive chemotherapy depends both on the 
histologic type and the presence of the residual tumour (Dhall et al., 2008). Those trials 
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which combine the systematic and intraventricular chemotherapy had better results only 
among children without metastases and residual tumour (Zeltzer et al., 1999) 
The survival of relapsed patients is very poor, especially in patients who had already 
received radiotherapy and/or auto-transplantation (Butturini et al., 2009). However, there 
are several trials by intensive chemotherapy and transplantations. (Park et al., 2010). The 
prolongation of the survival with metronomic therapy was possible in some studies. The 
metronomic therapy is referred to as low-dose chemotherapy or antiangiogenic 
chemotherapy (Kieran et al., 2005; Privitera et al., 2009; Sterba et al., 2010). Recently, the 
combination of the alkylating agent temozolomide with etoposide, which is a topoisomerase 
II inhibitor was found to be efficacious in prologing the survival in relapsed 
medulloblastoma. (Wang CH et al., 2009; Ruggiero A et al., 2010). However, the study of the 
application of the metronomic therapy for a longer time after the about 6 months long 
intensive and maintenance therapy in the primordial therapy of high risk cases may be 
justified too due to the occurrence of late relapses. 
The toxicity of the previously described chemotherapeutic modalities depends on their 
intensity independent from the well known side effects of the radiotherapy. The most 
common and most serious ones are the acut myelotoxic effect and infections. Some authors 
describe yet anorexia, nausea, diarrhoea, pain and hypokalemia. 
Better comparability of the different therapeutic modalities, improvement of results and the 
decrease of side effects are expected from the application of the molecular biologic 
procedures in the stratification and tailored therapy.  
4.2 Targeted treatment 
There is still not any new, successful, widely accepted therapeutic approach which can 
substitute or at least complement the standard treatment of medulloblastoma.  
Presently, targeted treatment exists only in SHH group among the four groups described by 
Northcott et al. (2010). In this group tumor proliferation is attributed to the lack of inhibition 
of SMO protein by loss of function of inhibitory Patched protein (Ptch1) or activating 
mutation of SMO. SMO inhibitors, as cyclopamin, IPI-926 and the orally available GDC-0449 
inhibit hedgehoge pathway. The latter went through a Phase 1 study, resulting in a 3-month 
long transient well-defined remission achieved in one 26-year old patient with proven Ptch1 
mutation (Rudin et al., 2009). 
Before the establishment of the new subgroups of medulloblastoma, there were also other 
molecularly targeted treatments. In some cases they were administered to some individual 
patients. Common feature of these treatments was the transient success, which finally 
turned into progression. The background of the progression could be the mutation of the 
targeted receptor or other involved proteins. 
One of these targets were somatostatin receptors (SSTR), which were recognized in 
medulloblastoma cell surface in late nineties of the last century (Fruhwald et al., 2004; 
Guyotat et al., 2001;). Several attempts were to bind radioactive isotope to its agonist 
octreotide or its derivates, providing localized, targeted radiotherapy, which did not show 
extra survival advantage above conventional irradiation, (Beutler et al., 2005). Somatostatin 
analogues themselves through SSTR receptors may inhibit cell proliferation. 
Medulloblastoma express high amount of SSTR based on Octreoscan examination (Muller et 
al., 1998). Only one patient was described who received only octreotide without radioactive 
isotope, and was a long term survivor (Glas et al., 2008). 
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Receptor tirozin kinases another possible target group. There are several drugs targeting 
these receptors which are also expressed in a certain part of medulloblastoma (ErbB2, 
PDGFR). Their increased expression usually results in worse survival and increased 
metastatic ability (Gilbertson et al., 1995; Gilbertson & Clifford, 2003). The most experience 
is reported with imatinib, which proved to be effective in vitro, however, in vivo successful 
human experiences are still missing (Abouantoun & MacDonald, 2009). This may be 
partially caused by their hindered penetration through blood brain barrier.  
Another possible therapeutic approach is the inhibition of histon deacetylases (HDAC). 
Acetylation of histones’ amino terminal tails by histon acetyltransferase relaxes the 
chromatin for transcription, and removal of acetyl groups by HDAC repress transcription 
(Roth et al., 2001; de Ruijter et al., 2003). Histon hypoacetylation and inappropriate 
transcriptional repression are hypothesized to be a key contributor to the development of 
human cancers (Marks et al, 2001; Marks & Dokmanovic, 2005). HDAC inhibitors have been 
shown to cause pleiotropic effect on human cancer cells, including apoptosis, cell cycle 
arrest and differentiation (Su et al., 2011). Valproic acid (VPA), an anticonvulsive drug is one 
of the recently discovered HDAC inhibitors. There is one published Phase 1 study in 
pediatric CNS tumors, 2 patients with medulloblastoma were included (Su et al., 2011). The 
treatment was well-tolerated, however response was not observed among this little cohort 
of patients with medulloblastoma. 
Another promising area in the treatment of medulloblastoma could be the administration of 
retinoic acid (RA). RA has been shown to have anticancer efficacy in a variety of cancers. 
Retinoic acid is commonly used in the treatment of certain childhood cancers. It is a drug 
with protean effects including cytodifferentiation, apoptosis, and inhibition of angiogenesis 
to name a few (Miller, 1998). RA has been shown in preclinical models to cause apoptotic 
cell death in medulloblastoma by promoting BMP-2 transcription (Hallahan et al., 2003). 
This results in production of soluble BMP-2 protein that induces p38 MAP kinase 
phosphorylation and ultimately apoptosis (Spiller et al., 2008). Recently a phase 3 trial has 
been opened to treat medulloblastoma with RA.  
There are several different approaches to try to kill medulloblastoma cells by means of 
immunotherapy. Only some of them were introduced in small series of pediatric patients 
with limited success. In the last decades of the twentieth century application of lymphokine 
actived killer (LAK) cells directly administered intrathecally with co-administration of 
human recombinant IL-2 for patients with recurrent disseminated medulloblastoma was 
published. Some of the limited number of patients showed long term survival (Okamoto et 
al., 1988; Silvani et al., 1994).  
Another method is the adoptive transfer of tumor-specific cytolytic T cells to the tumor bed 
and cerebrospinal fluid. This is an attractive strategy, but limited in its clinical application 
owing the paucity of defined antigens consistently expressed by medulloblastoma. So far 
only two in vitro animal medulloblastoma xenograft models have been published.  One is 
targeting IL13Receptor-alpha2 by genetically modified CD8+ citotoxic T-cells expressing an 
IL13-zetakine chimeric immunoreceptor (Stastny et al., 2007). The other model is targeting 
HER2 expression, which is a feature of the malignant phenotype of medulloblastoma 
(Gilbertson et al., 1995). Recruiting the cellular arm of the immune response to HER2 
positive tumor cells, genetically engineered HER2-specific T-cell with antigen binding 
property and lytic capacity were created. Adoptive transferred HER2-specific T-cells were 
administered in SCID mouse orthotopic medulloblastoma xenograft, which resulted in 
sustained regression of HER2 positive medulloblastoma, which might have resulted in a 
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promising immunotherapeutic approach (Ahmed et al., 2007). Phase 1 study of adoptive 
transfer of tumor-specific cytolytic T cells exists in patients with recurrent glioblastoma 
multiforme and neuroblastoma. 
Another immunotherapeutic method which is already investigated in human patients with 
recurrent medulloblastoma is based on dendritic cell-based tumor vaccination. Dendritic 
cells are the antigen presenting cells, which are present in central nervous system 
exclusively. Autologous mature dendritic cells loaded with tumor lysates derived from 
autologous, resected medulloblastomas were injected subcutaneously in 5 patients with 
medulloblastoma. Although the treatment was safe, no response was observed in any 
patient (Ardon et al., 2010). 
Natural killer (NK) cells display the highest cytolytic activity against tumor cells, and are 
considered suitable candidates for adoptive immunotherapy to treat cancer patients. 
Castriconi et al showed that in vitro medulloblastoma cell lines express ligands for 
activating NK-receptors, which makes medulloblastoma highly susceptible to NK-mediated 
cytolysis (Castriconi et al., 2007). However, human studies using NK-cells in 
medulloblastoma are lacking at this moment. 
5. Conclusions 
The therapy of medulloblastoma has changed during the last few decades which resulted in 
the improvement of the long-term survival up to almost 80%. This is due to the complex 
chemotherapy beyond the improved surgical and radiotherapeutical techniques. After 
cyclophosphamide, nitrosoureas and methotrexate more effective drugs would be applied 
in the treatment of medulloblastoma: carboplatin, cisplatin, etoposide and ifosfamide. In 
resistant or relapsed cases several other drugs are used, too, as Temozolomide. The 
preoperative therapy in spite of the encouraging pilot studies could not become a general 
practice. The high dose chemotherapy with autologous stem cell rescue seems to be effective 
to eradicate the remained tumour cells in high risk cases. The prolongation of the 
chemotherapy with cytostatic drugs in low doses and/or antiproliferative agents (retinoic 
acid, valproic acid, antiangiogenic agents) seems to be effective to prolong the remission in 
incurable cases. The chemotherapy is especially important in very young children (less than 
3 years old) because of the serious late side effects of radiotherapy. The targeted molecular 
therapy is promising, however, in spite of the several clinical studies the effectivity of 
molecular therapy is not proved yet in phase III. studies. 
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